Jonathan Slonin Pacira Bio Sciences, Inc. (PCRX) insider trading activity

Jonathan Slonin is Chief Medical Officer of Pacira BioSciences, Inc.. Currently has a direct ownership of 181,959 shares of PCRX, which is worth approximately $4.22 Million. The most recent transaction as insider was on Jun 03, 2025, when has been sold 5,084 shares (Common Stock) at a price of $26.4 per share, resulting in proceeds of $134,217. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 182K

2.72% 3M change

90.42% 12M change

Total Value Held $4.22 Million

JONATHAN SLONIN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 03 2025	SELL Payment of exercise price or tax liability	$134,217 $26.4 p/Share	5,084 Reduced 2.72%	181,959 Common Stock
Feb 01 2025	BUY Grant, award, or other acquisition	-	93,600 Added 33.35%	187,043 Common Stock
Jan 06 2025	SELL Open market or private sale	$16,173 $18.4 p/Share	879 Reduced 0.93%	93,443 Common Stock
Jan 02 2025	SELL Payment of exercise price or tax liability	$6,800 $18.33 p/Share	371 Reduced 0.39%	94,322 Common Stock
Aug 02 2024	SELL Open market or private sale	$18,947 $20.05 p/Share	945 Reduced 0.99%	94,306 Common Stock
Aug 01 2024	SELL Payment of exercise price or tax liability	$6,328 $20.75 p/Share	305 Reduced 0.32%	95,251 Common Stock
Jul 02 2024	SELL Open market or private sale	$80,117 $28.25 p/Share	2,836 Reduced 2.88%	95,556 Common Stock
Jul 01 2024	SELL Payment of exercise price or tax liability	$26,012 $28.46 p/Share	914 Reduced 0.92%	98,392 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$10,627 $24.32 p/Share	437 Added 0.44%	99,306 Common Stock
Jun 12 2024	BUY Grant, award, or other acquisition	-	54,300 Added 35.45%	98,869 Common Stock
Jun 11 2024	SELL Open market or private sale	$143,192 $28.57 p/Share	5,012 Reduced 10.11%	44,569 Common Stock
Jun 03 2024	SELL Payment of exercise price or tax liability	$49,887 $30.89 p/Share	1,615 Reduced 3.15%	49,581 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	5,000 Added 8.9%	51,196 Common Stock
Jun 07 2023	SELL Open market or private sale	$18,556 $37.87 p/Share	490 Reduced 1.33%	36,323 Common Stock
Jun 06 2023	SELL Open market or private sale	$18,364 $38.99 p/Share	471 Reduced 1.26%	36,813 Common Stock
Aug 03 2022	SELL Open market or private sale	$17,156 $55.7 p/Share	308 Reduced 0.82%	37,079 Common Stock
Jul 05 2022	SELL Open market or private sale	$52,844 $57.19 p/Share	924 Reduced 2.41%	37,387 Common Stock
Jun 08 2022	BUY Grant, award, or other acquisition	-	9,900 Added 20.63%	38,097 Common Stock
Jun 06 2022	SELL Open market or private sale	$22,216 $61.37 p/Share	362 Reduced 1.27%	28,197 Common Stock
May 23 2022	BUY Exercise of conversion of derivative security	$104,740 $52.37 p/Share	2,000 Added 6.54%	28,559 Common Stock
Aug 03 2021	BUY Grant, award, or other acquisition	-	5,000 Added 15.95%	26,350 Common Stock

Jonathan Slonin

Chief Medical Officer

Tampa, FL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PCRX shares.

Notify only if

Value

Insider Trading

Get notified when an Pacira Bio Sciences, Inc. insider buys or sells PCRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Pacira BioSciences, Inc.

Track Activities on PCRX

Account